Comparative Pharmacology
Head-to-head clinical analysis: AUSTEDO versus VALBENAZINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AUSTEDO versus VALBENAZINE.
AUSTEDO vs VALBENAZINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Deuterated tetrabenazine; inhibits vesicular monoamine transporter 2 (VMAT2), reducing dopamine uptake into synaptic vesicles and leading to decreased presynaptic dopamine release, similar to tetrabenazine but with altered pharmacokinetics due to deuterium substitution.
Vesicular monoamine transporter 2 (VMAT2) inhibitor, reducing dopamine release in the striatum.
Initial 6 mg orally once daily; titrate by 6 mg increments at weekly intervals to a maximum of 48 mg/day. For tolerability, may divide into twice daily dosing (e.g., 12 mg twice daily).
50 mg orally once daily; can be increased to 75 mg orally once daily based on tolerability and response.
None Documented
None Documented
Clinical Note
moderateValbenazine + Haloperidol
"The metabolism of Haloperidol can be decreased when combined with Valbenazine."
Clinical Note
moderateValbenazine + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Valbenazine."
Clinical Note
moderateValbenazine + Erythromycin
"The metabolism of Erythromycin can be decreased when combined with Valbenazine."
Clinical Note
moderateValbenazine + Cyclosporine
5-9 hours (parent); 7-10 hours (active metabolite). Steady state within 2-3 days.
Terminal elimination half-life is approximately 17-23 hours, allowing for once-daily dosing.
Urine (75-85% as metabolites, <5% unchanged); feces (10-15%)
Primarily hepatic metabolism; less than 30% of the dose excreted unchanged in urine and feces combined. Biliary/fecal excretion accounts for approximately 40-60% as metabolites.
Category C
Category C
VMAT2 Inhibitor
VMAT2 Inhibitor
"The metabolism of Cyclosporine can be decreased when combined with Valbenazine."